Epigenetic therapies in heart failure

J Mol Cell Cardiol. 2019 May:130:197-204. doi: 10.1016/j.yjmcc.2019.04.012. Epub 2019 Apr 13.

Abstract

Heart failure (HF) is a dominant cause of morbidity and mortality in the developed world, with available pharmacotherapies limited by high rates of residual mortality and a failure to directly target the changes in cell state that drive adverse cardiac remodeling. Pathologic cardiac remodeling is driven by stress-activated cardiac signaling cascades that converge on defined components of the chromatin regulatory apparatus in the nucleus, triggering broad shifts in transcription and cell state. Thus, studies focusing on how cytosolic signaling pathways couple to the nuclear gene control machinery has been an area of therapeutic interest in HF. In this review, we discuss current concepts pertaining to the role of chromatin regulators in HF pathogenesis, with a focus on specific proteins and RNA-containing macromolecular complexes that have shown promise as druggable targets in the experimental setting.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chromatin* / metabolism
  • Chromatin* / pathology
  • Epigenesis, Genetic / drug effects*
  • Heart Failure* / drug therapy
  • Heart Failure* / metabolism
  • Heart Failure* / pathology
  • Humans
  • Signal Transduction / drug effects*

Substances

  • Chromatin